HUTCHMED presents clinical data to be presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asian Congress

HONG KONG, SHANGHAI and FLORHAM PARK, NJ, November 5, 2024 (GLOBE NEWSWIRE) – HUTCHMED (China) Limited (“HATCHMED(Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the Phase III ESLIM-01 study of sovleplenib, as well as several investigator-initiated studies of compounds discovered by HUTCHMED, will be presented at the American Society. The Annual Meeting of Hematology (“ASH”) to be held December 7–10, 2024 in San Diego, USA, and the European Society of Medical Oncology (“ESMO”) 2024 Asian Congress to be held December 6–8, 2024. to Singapore.

Long-term safety and efficacy data from a follow-up open-label substudy of the phase III ESLIM-01 extension study of sovleplenib in adult patients with chronic primary immune thrombocytopenia (“ITP”) in China will be published. at the 2024 ASH Annual Meeting (NCT05029635). At the data cutoff date of January 31, 2024, a total of 179 patients had received at least one dose of sovleplenib. 55.3% (99/179) of patients were still receiving treatment in the substudy, with a mean treatment duration of 56.6 weeks.

Data from a subsequent extension study demonstrated that long-term treatment with sovleplenib was effective in increasing and maintaining platelet counts in adults with chronic primary ITP in China. In the overall population, overall response was achieved in 81% (145/179) of patients, with a sustained response rate of 51.4% and a long-term sustained response rate of 59.8%. The median cumulative duration of platelet count ≥50×10⁹/L was 38.9 weeks. Long-term treatment was well tolerated, the safety profile was consistent with previous studies, and no new safety signals were identified.

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative commercial-scale biopharmaceutical company. The company is engaged in the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has approximately 5,000 employees across all of its companies, centered around a team of approximately 1,800 oncology and immunology specialists. Since its inception, HUTCHMED has focused on delivering indigenously developed cancer drug candidates to patients around the world. The first three drugs are sold in China, the first of which is also approved in the US, Europe and Japan. For more information visit: www.hutch-med.com or follow us LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including, without limitation, its expectations regarding the therapeutic potential of fructintinib, savolitinib, sovleplenib and surufatinib, the continued clinical development of fructininib, savolitinib, sovleplenib and surufatinib, expectations regarding whether any studies will be fructintinib, savolitinib, sovleplenib and surufatinib meet primary or secondary endpoints, and its expectations regarding the timing of completion and publication of the results of such studies. Such risks and uncertainties include, but are not limited to, assumptions regarding the number of participants and the timing and availability of subjects meeting inclusion and exclusion criteria for the study; protocols or regulatory requirements; unexpected side effects or safety concerns; the ability of fructintinib, savolitinib, sovleplenib and surufatinib, including as combination therapies, to achieve a primary or secondary study endpoint, obtain regulatory approval in various jurisdictions and achieve commercial acceptance following receipt of regulatory approval; potential markets for fructintinib, savolitinib, sovleplenib and surufatinib for the targeted indication, as well as the adequacy of funding. In addition, because some studies are based on the use of serplulimab, sintilimab, S-1, temozolomide and bevacizumab as combination therapeutic agents, such risks and uncertainties involve assumptions regarding their safety, effectiveness, supply and continued regulatory approval. Current and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For a further discussion of these and other risks, please see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, the Stock Exchange of Hong Kong Limited and AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or for any other reason.

Medical information

This press release contains information about products that may not be available in all countries or may be available under different brands, for different indications, in different strengths or strengths. Nothing contained herein should be construed as solicitation, promotion or advertising of any prescription drugs, including those in development.

CONTACTS